# Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata

> **NCT03800979** · PHASE4 · COMPLETED · sponsor: **Institute of Dermatology, Thailand** · enrollment: 19 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT03800979
- **Lead sponsor:** Institute of Dermatology, Thailand
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-12
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-01-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03800979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03800979, "Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03800979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*